Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477846 | 1.00 | CTSL (0.49) | CTSLCTSBCTSKTSHRBCHE | |
| SCHEMBL16316719 | 1.00 | CTSL (0.49) | CTSLCTSBCTSKTSHRBCHE | |
| SCHEMBL22454254 | 0.85 | CTSL (0.51) | CTSLCTSBCTSKTSHRBCHE | |
| SCHEMBL24207209 | 0.82 | TSHR (0.50) | CTSLCTSBCTSKTSHRBCHE | |
| SCHEMBL12560332 | 0.82 | CTSL (0.43) | CTSLCTSBCTSKTSHRBCHE | |
| SCHEMBL12560331 | 0.82 | CTSL (0.43) | CTSLCTSBCTSKTSHRBCHE | |
| SCHEMBL12560330 | 0.82 | CTSL (0.43) | CTSLCTSBCTSKTSHRBCHE | |
| Methoxymethane SCHEMBL967072 | 0.81 | CTSL (0.48) | CTSLCTSBCTSKTSHRBCHE | |
| Methoxymethane SCHEMBL967074 | 0.81 | CTSL (0.48) | CTSLCTSBCTSKTSHRBCHE | |
| SCHEMBL19738349 | 0.81 | TSHR (0.41) | CTSLCTSBCTSKTSHRBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241408-A | Trifluoro methyl sulfide molecule as HIF2a inhibitor | 维眸生物科技(浙江)有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-2024349-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9193713-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2015-08-20 | — | — | US | disclosed |
| US-9006275-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2851366-A1 | Compounds as cannabinoid receptor ligands | Abbvie Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8841334-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8546583-B2 | Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2222165-B1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8492371-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2219629-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-08-25 | — | — | EP | disclosed |
| US-7750015-B2 | Nitrogen-containing heterocyclic compounds and methods of use thereof | SCHERING CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-7737155-B2 | Nitrogen-containing heterocyclic compounds and methods of use thereof | SCHERING CORPORATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2009048936-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080019978-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20070066630-A1 | Nitrogen-containing heterocyclic compounds and methods of use thereof | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CTSL 3390/4885CTSB 2384/4885CTSK 3100/4885 |
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | CTSL 1700/4885CTSB 1763/4885CTSK 3097/4885 |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | CTSL 981/4885CTSB 1096/4885CTSK 2386/4885 |
| US-20080019978-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1 | CTSL 2459/4885CTSB 2754/4885CTSK 2596/4885 |
| US-20070066630-A1 | Nitrogen-containing heterocyclic compounds and methods of use thereof | CYP11B2, CYP11B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CTSL 2259/4885CTSB 2899/4885CTSK 2618/4885 |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | OPRL1, OPRK1, OPRD1 | CTSL 1157/4885CTSB 1683/4885CTSK 1808/4885 |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | CTSL 1000/4885CTSB 1018/4885CTSK 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.